G protein-coupled receptor 88Genealiases: COCPMR · STRG
Q-omics provides the consensus-scored GPR88 profile across patient tissues and cancer cell-line models. GPR88 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GPR88 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, GPR88 RNA expression shows 15,498 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where GPR88 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR88 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR88 survival associations across molecular data types. GPR88 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR88 RNA expression–survival associations across cancer types. High GPR88 expression shows unfavorable associations in KIRP and DLBC, but favorable associations in SKCM, ACC, ESCA and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for GPR88 RNA expression.
This table summarizes GPR88 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for GPR88. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR88 shows lower tumor expression in COAD, BRCA, CHOL and READ and higher tumor expression in LUAD and KIRC. The COAD box plot shows higher GPR88 RNA expression in normal versus tumor tissue (log2 FC = −0.477, t-test p < 0.001).
This table shows molecular features associated with GPR88 in patient tissues and cancer cell lines. In patient samples, GPR88 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR88 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
